Background {#Sec1}
==========

Hodgkin lymphoma (HL), one of the most common lymphoproliferative diseases, characteristically presents with progressive and sequential enlargement of peripheral lymph nodes \[[@CR1]\]. Bone marrow (BM) invasion rarely occurs in patients with HL (approximately 3--5%) and typically only in those with advanced disease \[[@CR2]\]. However, Shah *et al.* \[[@CR3]\] reported a rare case of a patient with "primary bone marrow" Hodgkin lymphoma (PBMHL) with human immunodeficiency virus (HIV). PBMHL has also been reported in both HIV-positive and HIV-negative patients.

Epstein-Barr virus (EBV) is believed to play a causative role in HIV-associated HL \[[@CR4]\]. Use of *in situ* hybridization or immunohistochemical staining has revealed that approximately 40% of patients with non-HIV-associated HL \[[@CR5]\] and 75--78% of patients with HIV-associated HL are EBV-positive \[[@CR4], [@CR6]\]. The precise mechanism by which EBV contributes to development of HL remains unclear. EBV infection has no influence on the prognosis of children with HL \[[@CR7]\]. However, some researchers have reported a higher relapse rate after primary treatment in middle-aged patients with EBV-associated HL than in those with non-EBV-associated HL \[[@CR8]\]. In patients with refractory HL, dose-dense systemic chemotherapy, brentuximab vedotin (BV), and autologous hematopoietic stem cell transplant are considered salvage treatments. BV, which is a CD30-directed antibody conjugated with monomethyl auristatin E, is an approved treatment for patients with relapsed or refractory HL \[[@CR9]\], and it has safely been combined with systemic chemotherapy \[[@CR10]\]. In this report, we present a case of a patient with EBV-associated PBMHL who was successfully treated with BV-containing combination chemotherapy.

Case presentation {#Sec2}
=================

A 38-year-old Japanese man was admitted to our hospital because of progressive fever and thrombocytopenia for more than 1 month. His medical history included Burkitt lymphoma (negative for EBV-encoded small ribonucleic acid (RNA)), and he had been treated with hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) 12 years before admission. He had achieved complete remission. He was a daily smoker (18 pack-years) and took no daily medications. He had a family history of hypertension and denied having any malignancies.

The patient's physical examination findings were normal except for small papules on his upper back. Laboratory tests showed pancytopenia, high C-reactive protein, and a negative result for HIV (Table [1](#Tab1){ref-type="table"}). Computed tomography (CT) revealed moderate pulmonary emphysema with no evidence of infection or inflammation. Positron emission tomography/CT was unavailable for financial reasons. A skin biopsy of his rash revealed no malignant change. BM examination revealed hemophagocytosis without abnormal cells. Plasma viral deoxynucleic acid (DNA) was investigated to identify possible causes of hemophagocytosis, and the patient was found to be EBV DNA-positive (170,000 copies/ml).Table 1Laboratory findings on admissionComplete blood countCoagulationBiochemistryWBC3300/μlAPTT32.2 sTP6.2 g/dlIgG1145 mg/dlNeu77.00%PT60%Alb3.8 g/dlIgA194 mg/dlLym12.00%FDP8.4 μg/μlAST18 IU/LIgM28 mg/dlMo5.00%Fibrinogen442 mg/dlALT17 IU/LsIL-2 receptor7020 U/mlEos0.00%LDH273 IU/Lβ~2~-MG1.4 μg/dlBas0.00%γ-GTP28 IU/LIL-620.6 pg/mlAty lym5.00%T-Bil1.3 mg/dlIFN-γ6.3 IU/mlRBC331 × 10^4^/μlBUN13.7 mg/dlTNF-αNegativeHb10.6 g/dlCre0.68 mg/dlProcalcitonin0.06 ng/mlHct31.00%Na^+^135 mEq/LHIV antibodyNegativeMCV93.7 flK^+^4.4 mEq/LParvovirus IgMNegativePlt10.6 × 10^4^/μlCl^−^102 mEq/LParvovirus IgGPositiveCD4^+^ T cells220/μlCRP5.87 mg/dlHHV-6 IgMNegativeFe46 mg/dlHHV-6 IgGPositiveFerritin771 ng/mlC7-HRPNegativeEB EA IgGNegative(EIA index = 0.4)EB VCA IgMNegative(EIA index = 0.5)EB VCA IgGPositive(EIA index = 12.1)EBNA IgGPositive(EIA index = 2.5)EBV DNA4200 copies/ml*Abbreviations: WBC* White blood cells, *APTT* Activated partial thromboplastin time, *TP* Total protein, *IgG* Immunoglobulin G, *Neu* Neutrophils, *PT* Prothrombin time, *Alb* Albumin, *IgA* Immunoglobulin A, *Lym* Lymphocytes, *FDP* Fibrinogen degradation product, *AST* Aspartate aminotransferase, *IgM* Immunoglobulin M, *Mo* Monocytes, *ALT* Alanine aminotransferase, *sIL-2* Soluble interleukin 2, *Eos* Eosinophils, *LDH* Lactate dehydrogenase, *β*~*2*~*-MG* β~2~-microglobulin, *Bas* Basophils, *γ-GTP* γ-Glutamyltransferase, *IL-6* Interleukin 6, *Aty lym* Atypical lymphocytes, *T-Bil* Total bilirubin, *IFN-γ* Interferon-γ, *RBC* Red blood cells, *BUN* Blood urea nitrogen, *TNF-α* Tumor necrosis factor-α, *Hb* Hemoglobin, *Cre* Creatinine, *Hct* Hematocrit, *HIV* Human immunodeficiency virus, *MCV* Mean corpuscular volume, *Plt* Platelets, *CRP* C-reactive protein, *HHV-6* Human herpesvirus 6, *C7-HRP* Cytomegalovirus antigenemia, *EB EA IgG* Epstein-Barr virus early antigen immunoglobulin G, *EB VCA* Epstein-Barr virus viral capsid antigen immunoglobulin M, *EIA* Enzyme immunoassay, *EBNA* Epstein-Barr nuclear antigen

As recommended by a previous report, the patient's EBV-associated hemophagocytic lymphohistiocytosis (HLH) was treated with chemotherapy comprising etoposide and dexamethasone \[[@CR11]\]. Shortly after initiation of chemotherapy, his white blood cell count recovered to within the normal range, and his plasma EBV DNA became undetectable. However, his EBV DNA turned positive (290 copies/ml), and his white blood cell count declined again 7--9 weeks later. A second BM sample showed infiltration with Reed-Sternberg (RS)-like cells (Fig. [1a, b](#Fig1){ref-type="fig"}) that were positive for CD30 (Fig. [1c](#Fig1){ref-type="fig"}), EBER-1 (Epstein-Barr encoding region 1) (Fig. [1d](#Fig1){ref-type="fig"}), CD15 (Fig. [1e](#Fig1){ref-type="fig"}), Bob-1 (Fig. [1d](#Fig1){ref-type="fig"}), and PAX-5 (Fig. [1e](#Fig1){ref-type="fig"}) but negative for Oct-2, CD3, CD20, surface immunoglobulin, and CD56. Another CT examination showed neither lymphadenopathy nor hepatosplenomegaly. The patient was eventually diagnosed with PBMHL (Ann Arbor stage IVB, International Prognostic Index high-intermediate risk). Previous reports have indicated that PBMHL progresses rapidly and that combination chemotherapy (Adriamycin, bleomycin, vinblastine and dacarbazine \[ABVD\]-like or cyclophosphamide, Adriamycin, vincristine and prednisone \[CHOP\]-like regimens) is ineffective, as shown in Table [2](#Tab2){ref-type="table"}. Because some patients with EBV-associated lymphoproliferative disease express P-glycoprotein, which is a multidrug resistance 1 (MDR1) gene product \[[@CR12]\], the poor prognosis of PBMHL may be related to the presence of the *MDR1* gene. DeVIC (dexamethasone, etoposide, ifosfamide, and carboplatin) includes ifosfamide and carboplatin, which are MDR-unrelated anticancer agents.Fig. 1Histopathological findings in bone marrow on presentation. Representative photomicrographs of hematoxylin and eosin (HE) and immunohistochemically stained sections of bone marrow. Rectangular area in (**a**) (HE, × 40) is shown at higher magnification in (**b**) (HE, original magnification × 400). Reed-Sternberg cell-like cells are present (*arrowhead*). These cells are positive for CD30 (**c**, original magnification × 400), Epstein-Barr encoding region *in situ* hybridization (EBER-ISH) (**d**, original magnification × 400), CD15 (**e**, original magnification × 400), Bob-1 (**f**, original magnification × 400), and PAX-5 (**g**, original magnification × 400). The small rectangulars in **d**--**g** show expression of CD30 in the same field. *Arrowheads* in **f** and **g** identify the CD30 positive malignant cellsTable 2Compilation of published reports of patients with primary bone marrow Hodgkin lymphomaPatient backgroundAge (years)SexCD4 countCD15CD30EB virusTherapiesSurvival (months)ReferenceNon-HIV20FNo dataNDNDNDMOPP9\[[@CR15]\]Non-HIV72FNo data++EBER1^+^THP-COP1\[[@CR16]\]Non-HIV64MNo data^a^++NDABVD1\[[@CR17]\]Non-HIV50MNo data^b^++LMP1^+^ABVD1\[[@CR18]\]Non-HIV66FNo data^a^++EBER1^+^A(B)VD15\[[@CR19]\]Non-HIV68MNo data^a^ND+EBER1^+^ND1\[[@CR20]\]Non-HIV89FNo data^b^--+NegativeNDND\[[@CR21]\]AIDS58M20++NDABVD2\[[@CR22]\]AIDS36M31++NDABVD4AIDS31M549++NDABVD18AIDS49M54++NDABVD114AIDS33M104++NDEBV^a^4AIDS34M86++NDABVD3AIDS29M193NDNDNDMOPP31\[[@CR23]\]AIDS55M14NDNDNDNDND\[[@CR24]\]AIDS43M179++NDABVDND\[[@CR3]\]AIDS26MNo data++NDNDND\[[@CR25]\]AIDS29FNo data+--NDNDNDAIDS27M195++NDNDNDAIDS34M17++NegativeNDNDAIDS26M39++NDNDNDAIDS31M123++NDNDNDAIDS49M52++NDNDNDAIDS40M56++NDNDNDAIDS35M104++LMP1^+^NDNDAIDS41M237++NDNDNDAIDS51M282++LMP1^+^NDNDAIDS42M198++NDNDND*Abbreviations: AIDS* Acquired immunodeficiency syndrome, *HIV* Human immunodeficiency virus, *MOPP* Mechlorethamine, vincristine, procarbazine, and prednisone, *THP-COP* Pirarubicin, cyclophosphamide, vincristine, and prednisolone, *ABVD* Adriamycin, bleomycin, vinblastine and dacarbazine, *ND* No data, *EBER1* Epstein-Barr virus-encoded RNA 1, *LMP1* Latent membrane protein 1, *EB* Epstein-Barr virus^a^Leukocytopenia (under 3500/μl) but no CD4 count available^b^Lymphocytopenia (under 1000/μl) but no CD4 count available

In addition, because of coexisting pulmonary emphysema, DeVIC therapy was initiated at 12 weeks from onset. Although DeVIC therapy induced transient recovery of pancytopenia, it recurred with high plasma EBV DNA titers (2300 copies/ml) after the second course of DeVIC therapy (19--20 weeks from onset). Because a third BM examination revealed residual RS cells, the patient's disease was considered refractory to DeVIC therapy. After giving informed consent, he was further treated with BV (1.2 mg/kg) and AVD (Adriamycin, vinblastine, and dacarbazine) as described in a previous report \[[@CR12]\]. His peripheral blood cell count recovered without support of medication, and the RS cells disappeared. After four courses of combined chemotherapy, BV monotherapy was continued for 8 months, during which both soluble interleukin (IL)-2 receptor and plasma EBV DNA titers remained within the normal range. The patient declined autologous hematopoietic stem cell transplant. To date, no evidence of relapse has been detected.

Discussion {#Sec3}
==========

The overall incidence of BM involvement in HL is reportedly 5% \[[@CR2]\]. However, approximately 40--50% of patients with HIV-associated HL have BM invasion, and these patients commonly present with an advanced stage of disease (mainly stage IV). PBMHL is characterized by solitary BM invasion with HL. PBMHL has been reported in patients with and without HIV infection (Table [2](#Tab2){ref-type="table"}). Our review of published reports revealed that patients with acquired immunodeficiency syndrome or older patients are more likely to develop PBMHL. Although our patient was HIV-negative, his number of CD4^+^ T cells was low (200/μl). As shown in Table [2](#Tab2){ref-type="table"}, low CD4^+^ T-cell counts (or lymphocytopenia) are common in patients with PBMHL, especially in those with HIV-associated PBMHL, in whom CD4^+^ T-cell counts are reportedly 133 ± 130/μl (range 14--549/μl, median 103/μl).

Our patient developed HLH as the first symptom of HL. Although HL-associated HLH is rare, a previous retrospective study showed that EBV was frequently detected in patients with HL-associated HLH \[[@CR13]\]. Patients with HIV-associated HL, in whom HLH is more common, also exhibit a high prevalence of EBV. These findings suggest that patients with HL-associated HLH might have an unclear underlying immune disturbance for EBV. Our patient's case indicates that clinicians should perform BM biopsies to check for PBMHL in patients with (1) pancytopenia, (2) low CD4^+^ T-cell counts (or lymphocytopenia), and (3) EBV DNA positivity.

As for the prognosis of PBMHL, only a few patients achieve long-term remission (Table [2](#Tab2){ref-type="table"}). When our patient's PBMHL proved refractory, we selected BV with AVD as salvage therapy for the following reasons. First, because of its rarity, there is no established treatment strategy for this disease, and therapeutic outcomes using ABVD- or CHOP-like regimens are reportedly poor (as shown in Table [2](#Tab2){ref-type="table"}). Second, bleomycin was contraindicated for our patient because of his coexisting moderate emphysema. Third, a combination of BV with AVD was significantly superior to BV with ABVD \[[@CR10]\]. Fortunately, our patient completed his planned therapy without relapse. To the best of our knowledge, this is the first reported case of successful treatment of HIV-negative PBMHL with BV.

The association of EBV and HL has been investigated; however, the exact mechanism involved remains unclear. Approximately 40% of patients with non-HIV-associated HL are EBV-positive \[[@CR5]\]; the rate of EBV positivity is much higher in patients with HIV-associated HL \[[@CR4], [@CR6]\]. In addition to *in situ* hybridization and histopathological staining, plasma EBV DNA titers are also a useful biomarker for monitoring prognosis in patients with EBV-associated HL \[[@CR14]\]. In our patient, an increase in EBV DNA titer preceded recurrence of pancytopenia and occurred earlier than the increase in soluble IL-2 receptor titer. Plasma EBV DNA titers may be helpful for early detection of recurrence of PBMHL.

Conclusions {#Sec4}
===========

We present a rare case of a patient with PBMHL without HIV infection. More experience is needed to establish the optimum treatment for this disease. On the basis of our patient's progress, we propose that combined therapy with BV and AVD could be a therapeutic option for PBMHL.
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